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Abstract.  Components of the extracellular matrix have 
been shown to modulate the interaction of endothelial 
cells with their microenvironment.  Here we report that 
thrombospondin (TSP),  an extracellular matrix compo- 
nent,  induces adhesion and spreading of murine lung 
capillary (LE-II) and bovine aortic (BAEC) endothelial 
cells. This TSP-induced spreading  was inhibited by 
heparin and fucoidan,  known to bind the amino- 
terminal globular domain of the molecule.  In addition, 
endothelial cells were induced to migrate by a gra- 
dient of soluble TSP (chemotaxis).  The chemotactic 
response was inhibited by heparin and fucoidan, as 
well as by the mAb A2.5, which also binds to the 
amino-terminal  domain.  These data are in agreement 
with our previous observation that the TSP amino- 
terminal  heparin binding region is responsible for the 
induction of tumor cell spreading  and chemotactic mo- 
tility.  The inhibition of chemotaxis and spreading by 
antibodies against the/33 but not the E1 chain of the 
integrin receptor points to a role for the integrins  in 
the interaction of endothelial cells with TSP. 
We also found that TSP modulates endothelial cell 
growth.  When added to quiescent LE-II cells, it in- 
hibited the mitogenic effects of serum and the angio- 
genic factor bFGF, in a dose-dependent manner.  The 
inhibition of DNA synthesis detected in the mitogenic 
assay resulted in a true inhibition of BAEC and LE-II 
cell growth,  as assessed by proliferation assay.  This 
work indicates that TSP affects endothelial cell adhe- 
sion,  spreading,  motility and growth.  TSP, therefore, 
has the potential to modulate the angiogenic process. 
C 
OMPONENTS of the extracellular  matrix (ECM) ~  have 
been shown to interact  with endothelial  ceils and to 
regulate  such  cellular functions  as attachment  and 
spreading,  motility, and response to growth and transform- 
ing factors.  Thus, the ECM may help maintain  the integrity 
of the vessel wall, mediate the endothelium's interaction with 
platelets and other cells, regulate tissue repair and remodel- 
ing during would healing,  and participate in angiogenesis 
and in pathological  conditions,  such as tumor metastasis. 
Thrombospondin (TSP) is a high-molecular  weight mul- 
tifunctionai glycoprotein (9, 19, 37). It was first described as 
a product of platelets, released from the alpha granules in re- 
sponse to activation by thrombin.  Later TSP was shown to 
be produced in vitro by a  variety of cell types including 
fibroblasts,  smooth  muscle  cells,  pneumocytes,  macro- 
phages,  keratinocytes,  monocytes, osteoblasts,  and tumor 
cells (10, 12, 13, 19, 21, 26, 35, 37, 44). In addition,  it is syn- 
thesized,  secreted in the culture medium, and incorporated 
into the ECM by cultured endothelial  cells (16, 25, 26, 31). 
In vivo TSP has been found in plasma, on the surface of acti- 
1. Abbreviations used in this paper: ECM, extracellular matrix; FN, fibro- 
nectin; LM, laminin; TSP, thrombospondin. 
vated platelets,  in endothelial  cell cytoplasm, and in base- 
ment membranes and  vessel walls  (45).  TSP can interact 
with  different  macromolecules,  including  several  compo- 
nents of the ECM (19), and with specific receptors on the cell 
surface (1, 2, 14, 20, 33, 41, 46), thus mediating cell-cell and 
cell-substrata interactions.  TSP has been reported to induce 
attachment,  spreading,  motility, and growth of different cell 
types (22, 35, 38, 42, 43). 
TSP appears to play a role in tissue neoformation,  healing, 
remodeling,  and in several pathologies.  For example:  (a) it 
is synthesized  by tumor cells,  and the concentration in the 
tumor mass is higher than in normal tissues (30, 35, 44); (b) 
TSP incorporation into the ECM is transient,  and it is readily 
removed by heparitinase and heparin-like molecules (24); (c) 
TSP concentrations  are also high at the site of vascular and 
tissue injury (45); (d) in vitro the production of TSP and its 
deposition into the ECM depends on the cell cycle, degree 
of confluency and level of differentiation (16, 26). It is higher 
under conditions of injury (heat shock) (15) and can be in- 
creased by PDGF (21), basic FGF, and IL 1 (Danoviel, J. B., 
and P. Bornstein.  1988. J.  Cell Biol.  107:596a. [Abstr.]);  (e) 
TSP has been shown to function as an autocrine growth reg- 
ulatory factor for smooth muscle cells and to increase the 
mitogenic effect of EGF on these cells (22, 23). 
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TSP with endothelial cells. We analyzed the effect of TSP on 
endothelial cell adhesion, spreading, and motility. Prolifera- 
tion and mitogenesis assays were performed to investigate 
whether TSP regulates cell growth. The results indicate that 
TSP affects important endothelial cell functions, and modu- 
lates the response to growth and angiogenic factors. These 
data strengthen the hypothesis that TSP has a role in wound 
healing and remodeling, and indicate that TSP has the poten- 
tial to modulate angiogenesis. 
Materials and Methods 
Calcium-replete  TSP  was  purified  from  the  supernatant  of thrombin- 
stimulated fresh human platelets, essentially as described (11). Laminin was 
purified from Engelbreth-Holm-Swarm (EHS)  tumor as described (39). 
Fibronectin was purchased from Collaborative Research (Bedford, MA); 
type IV collagen and gelatin were from Sigma Chemical Co.  (St. Louis, 
MO). Rabbit polyclonal antiserum against platelet GpllblIIa was a kind gift 
from Dr.  E. Dejana (Istituto Mario Negri, Milano, Italy). This antibody 
was shown to react with both murine and bovine endothelial cell lines, as 
assessed by fluorescence flow cytometry, with 73.5%  (BAEC) and 76.3% 
(LE-II) positive cells. Irnmunoblot analysis of endothelial cell extract was 
done as described (4), and showed reactivity of the antiserum with a band 
of 90 kD, as described for an anti-B3 antibody (4), and as expected for en- 
dothelial cells. A2.5 mAb was kindly provided by Dr. W. Frazier (Washing- 
ton University School of Medicine, St. Louis, MO); the antibody against 
the fibronectin receptor was generously provided by Dr.  R.  L.  Juliano 
(University of North Carolina, School of Medicine, Chapel Hill, NC); hu- 
man recombinant basic FGF (bFGF) was kindly provided by Dr. E  Ber- 
tolero (Erbamont, Milano, Italy). 
Cells 
BAEC  bovine aortic  endothelial cells were kindly  provided by  Dr.  E. 
Dejana (Istituto Mario Negri, Milano, Italy). BAEC cells and LE-II murine 
lung capillary cells (36) were cultured in DME supplemented with gluta- 
mine and 10%  FCS (LE-II) or 20%  FCS (BAEC). Cells were tested and 
found positive by immunofluorescence for the yon Willebrand factor,  a 
marker of endothelial cells. For adhesion and motility experiments, cells 
were detached by brief exposure to trypsin 0.025%/EDTA 0.02%, and al- 
lowed to regenerate for 1 h in serum-containing medium. 
Cell Adhesion Assay 
A solution of TSP was diluted to the indicated concentrations (for routine 
experiments 10/~g/ml) in Dulbecco's PBS (DPBS), and 40/~1 were added 
to each well of a 96-well plate (Falcon Pro-bind; Becton-Dickinson Co., 
Lincon Park, NJ). The plate was incubated at 37°C for 2 h, then washed 
twice with DPBS, and the nonspecific binding sites were saturated by 30 
rain incubation with 1% BSA in serum-free medium. Cells were washed 
three times in serum-free medium, resuspended at the concentration of 5 
x  lO~/ml in serum-free medium supplemented with 0.1% BSA, and added 
to the wells (100/~l/well).  The assay was incubated for 30-90 min at 37°C, 
since preliminary experiments showed that  adhesion and  spreading in- 
creased up to "~40 min, but not after that time. 
The wells were then gently washed four times with DPBS and the adher- 
ent cells were fixed and stained with 0.5% crystal violet in 20% methanol, 
rinsed, and air-dried. The percentage of spread cells compared with the to- 
tal adhered cells was calculated, by counting attached and spread cells in 
at least three high-power fields, then the stain was eluted with an ethanol:0.1 M 
sodium citrate (1:1) solution and absorbance at 540 nm was measured with 
a Multiscan MC (Titertek; Flow Laboratories, Milano, Italy). In some ex- 
periments, to prevent protein synthesis and secretion, cells were treated 
with cycloheximide (20 ttM) or monensin (1 ttM), as described (5). Briefly, 
cells were pretreated with the inhibitors for 60 min at room temperature, 
in serum-containing medium. The inhibitors were also maintained during 
the assay. 
Cell Motility Assay 
Chemotaxis and haptotaxis were assayed using modified Boyden chambers, 
with 8 (LE-II) and 5 #m (BAEC) pore size polycarbonate PVP-free Nucleo- 
pore filters. 
For haptotaxis, filters were coated on one side by floating them overnight 
at 37°C on a solution of attractant in DPBS, as described (38). The filters 
were washed four times in DPBS and once in distilled water and then air- 
dried. Chambers were assembled with serum-free medium containing 0.1% 
BSA. The side of the filter with the highest protein concentration faced the 
lower compartment. 
For chemotaxis the filters were prepared by immersing them overnight 
in a solution of 100 tzg/ml gelatin in 0.1% acetic acid and then air-dried. 
Chemotaxis was conducted as described (38). Briefly, different dilutions of 
the attractant in DME with 0.1% BSA were added to the lower compartment 
of the Boyden chamber, with or without inhibitors. Cells (1-2  x  106/ml) 
in serum-free medium containing 0.1% BSA were added to the upper com- 
partment of  the chamber. After 4-5 h incubation at 37°C filters were stained 
with Diff Quick (Merz-Dade, Diidingen, Switzerland), and the migrated 
cells in 10 high-power fields were counted. 
Mitogenesis and Proliferation  Assay 
For the mitogenesis assay,  LE-II cells were seeded 104/well in 0.1 ml of 
medium supplemented with 10% FCS in the inner wells of a 96-well tissue 
culture plate. After 3 d, the supernatant was replaced with 0.1 ml medium 
containing 0.5 % FCS.  Cells were starved for 48 h and then serum-free 
medium containing the samples to be tested was put in the wells; 20 h later 
[3HITdR  (1  #Ci/well) was added. After 3 h exposure to thymidine, ceils 
were washed three times, and the radioactivity was measured in a scintilla- 
tion counter after precipitation with TCA.  In some cases the wells were 
coated with TSP before addition of the cells, following the same procedures 
as for the a~ihesion assay. 
The cell proliferation assay was performed essentially as described by 
Schreiber et al. (36). Briefly,  l03 BAEC or LE-II cells were plated in each 
well of a 96-well cluster dish, in serum containing medium. After 24 h the 
supernatant was replaced with serum-free medium containing the samples 
to be tested. After 3 d of incubation, the cells were washed and processed 
as described for the adhesion assay. 
Results 
TSP-induced Adhesion and Spreading of 
Endothelial Cells 
Murine lung capillary (LE-II) and bovine aortic (BAEC) en- 
dothelial  cells  adhered  and  spread  on  TSP-coated  plastic 
(Figs. 1 and 2). Adhesion and spreading of the two cell types 
were detectable when the plastic was coated with a solution 
of TSP at the concentration of 5/~g/ml (10 nM) or higher. 
A  representative  experiment  showing  the  adhesion  and 
spreading  of LE-II cells to increasing concentrations of TSP 
is shown in Fig. 1. Compared with FN, TSP induced a simi- 
lar degree of cell attachment  (not shown). Spreading  was re- 
producible,  up to 84 and 90%  for BAEC  and LE-II cells, 
respectively, at a TSP concentration of 50/zg/ml (Fig. 2, b 
and e).  However, the degree of spreading  was usually less 
than on a FN substrate. 
We  next  investigated  the  role  of protein  synthesis  and 
secretion  in  TSP-induced  adhesion  and  spreading  of en- 
dothelial cells. Treatment of BAEC with cycloheximide (20 
/~M) and monensin (1 #M) resulted in a significant reduction 
of TSP-induced cell attachment  (56.3 % inhibition for cyclo- 
heximide and 54.4% for monensin), whereas spreading  was 
not affected (0 and 3 % inhibition compared with untreated 
cells). LE-II spreading and, at a less extent, attachment  were 
partially  affected by treatment  with cycloheximide (22.3% 
inhibition of spreading  and 13.6% inhibition of attachment) 
and monensin (34.1  and  11.5% inhibition of spreading  and 
attachment,  respectively). 
The inhibitory effects of the TSP-binding  molecules hepa- 
rin and fucoidan were tested to identify the molecular do- 
main responsible for adhesion.  Both molecules bind to the 
amino-terminal small globular domain of the TSP, and have 
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Figure 1.  TSP-induced adhesion (t2) and spreading (,) of LE-II 
cells. Solutions at different concentrations of TSP were used to coat 
the plastic surface. Adhesion is expressed as absorbance (×103), 
and spreading is expressed as the percentage of spread cells, evalu- 
ated in three high-power fields. Each point is the mean of at least 
three values. 
been shown to inhibit the attachment and spreading of hu- 
man melanoma cells to TSP (35).  The inhibitory effect of 
heparin on cell adhesion was not significant, but fucoidan, 
at a concentration of 100 #g/mi, partially affected the adhe- 
sion of LE-U and BAEC cells to TSP (Table I). Both heparin 
and fucoidan significantly inhibited endothelial cell spread- 
ing (Table I and Fig. 2), in agreement with the described role 
of the amino-terminal heparin-binding domain of TSP in cell 
spreading (35). 
Antibodies against potential TSP receptors were tested for 
their ability to inhibit endothelial cell adhesion. An integrin 
receptor containing the/33 chain has been shown to interact 
with TSP (20, 41). An antiserum directed against the integrin 
receptor IIblIIa (containing the f13 chain) partially inhibited 
the adhesion of LE-II to TSP,  and  strongly inhibited their 
spreading on TSP-coated substrata (Table I). In contrast, an- 
tibodies against the fibronectin receptor (a5/~l) had little in- 
hibitory effect on the adhesion or spreading of LE-II cells 
(Table I), at a dose that inhibited adhesion on fibronectin (not 
shown).  These antibodies had  less  effect on BAEC  cells: 
none affected adhesion, and the inhibitory effect on spread- 
ing was comparable for the anti-IIblIIa and anti-fibronectin 
receptor antibody. A control nonimmune serum, and a rabbit 
antiserum against laminin, tested at the same dilutions, had 
no significant effect on attachment and spreading of LE-II 
and BAEC cells on TSP (not shown). 
We next investigated the role of the GRGDS peptide on 
TSP-mediated endothelial cell adhesion and  spreading.  In 
both cell lines, the GRGDS peptide significantly inhibited 
cell spreading, and partially affected cell attachment (Table 
I). The control GRGES peptide had almost no effect in this 
assay (Table I). 
Chemotactic Response to TSP 
Thrombospondin stimulated the motility response in both 
endothelial cell lines. LE-II cells migrated in response to a 
gradient of soluble TSP (chemotaxis) in  a  concentration- 
dependent manner,  reaching a  plateau  at  150  ~g/ml  (300 
nM) (Fig. 3). LE-II motility response was time-dependent, 
reaching maximal motility after 4  h  (not shown).  TSP,  at 
concentrations of 5-50 izg/ml, induced endothelial cell hap- 
totactic migration (i.e., a motility response induced by a gra- 
dient of substrate-bound TSP) in a dose-dependent manner 
(not shown). 
Figure 2. Adhesion and spreading of LE-II (a, b, and c) and BAEC (d, e, and f) to fibronectin (a and d), thrombospondin (b and e) and 
thrombospondin in the presence of 100/xg/ml fucoidan (c and f). Substrata were prepared as described in Materials and Methods, using 
a solution of 10 ~g/ml of fibronectin or 20 #g/ml TSP. Cells were fixed with 2.5%  glutaraldehyde in DPBS. 400x. 
Taraboletti et al.  Thrombospondin Affects Endothelial Cell Behavior  767 Table I. TSP-induced Endothelial  Cell Attachment and Spreading: Effect of lnhibitors 
LE-II 
Inhibitor  Dose  Adhesion  Spreading 
BAEC 
Adhesion  Spreading 
/z  g /ml 
Heparin  200  81.5  ±  6.5  49.8  ±  7.6* 
100  93.5  ±  4.6  68.0  ±  9.1" 
10  85.4  ±  5.2  83.0  ±  9.0 
1  112.6  +  7.2  91.5  ±  3.5 
Fucoidan  100  71.8  ±  2.2*  45.7  5:  9.6* 
10  97.8  ±  20.9  62.5  5: 4.5* 
1  104.4  +  8.8  87.0  5:14.0 
Anti-IIblIIa  1:40  75.2  +  12.3  36.7  5:  14.1" 
Anti-FN Rec  30  88.3  ±  0.7  86.0  5:5.0 
GRGDS  100  71.5  ±  5.8*  45.4  ±  5.0* 
10  81.2  ±  6.1  58.7  ±  5.5* 
1  84.7  ±  3.6  96.8  5:5.5 
GRGES  100  103.1  ±  3.6  85.5  5:  5.9* 
10  101.2  ±  2.1  97.7  ±  7.7 
1  100.3  ±  1.2  90.9  ±  1.7 
107.7  ±  6.0  72.7  +  3.5* 
84.2  ±  21.7  71.3  ±  7.2* 
89.6  ±  14.8  83.0  ±  3.0* 
95.6  ±  6.5  88.0  ±  1.0 
60.4  ±  5.5*  38.0  ±  10.7, 
88.4  +  4.1  75.0  ±  2.0* 
94.7  ±  4.7  85.0  +  4.0* 
99.5  ±  1.5  76.0  +  12.0 
100.7  ±  3.5  64.0  ±  4.0 
63.0  ±  3.9*  4.1  ±  2.6* 
62.8  5:  1.9,  70.0  ±  5.7* 
68.9  ±  1.7,  95.4  ±  7.0 
87.5  5:0.7  105.2  5:3.1 
90.1  5:3.9  99.5  5:1.9 
87.6  ±  2.2  90.4  ±  12.3 
Results are expressed as percentage of response obtained with TSP (20 ttg/ml), without 
experiment representative of two to six experiments. 
* P < 0.05 and * P < 0.005 compared with control (t test). 
any inhibitor (control =  100). Data are mean 5: SE of triplicate of one 
Most of the studies to characterize the motility response 
to TSP were done with LE-II cells, although TSP also in- 
duced a concentration-dependent  motility response in BAEC 
cells. In this case, the peak of activity was observed at TSP 
concentrations of 10-25 #g/ml, and there was less response 
at higher doses (not shown). 
To assess the random or directional nature of TSP-induced 
motility, we made a checkerboard analysis. In this assay cells 
are  exposed to different gradient  conditions,  obtained by 
varying the amounts of TSP added to the upper and lower 
compartment of the Boyden chamber (Fig. 4). A motility re- 
sponse is considered random when it is not gradient depen- 
dent; a true chemotactic response occurs only in the pres- 
ence of a positive gradient of the attractant. The diagonal in 
the figure represents the null gradient, when the TSP concen- 
trations on both sides of  the filter are identical. This diagonal 
separates the conditions of positive gradient (higher doses in 
the lower compartment of the chamber, below the diagonal) 
from the negative gradient (higher doses added to the com- 
partment with the cells, above the diagonal). We found that 
a positive gradient gave the strongest stimulation of migra- 
tion.  However, positive (bottom left),  negative (top right), 
and null (bottom right) gradients all induced cell migration, 
indicating  that  TSP-induced endothelial  cell  motility  has 
both directional and random components. 
Effect of Heparin, Fucoidan, and A2.5 Antibody on 
TSP-induced Chemotaxis 
Heparin,  fucoidan,  and mAb A2.5 bind to the amino-ter- 
minal domain of TSE and inhibit the TSP-induced chemotac- 
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Figure 3.  LE-II chemotactic response to TSP.  Increasing doses of 
TSP were added to the lower compartment of the Boyden chamber. 
Data are mean +  SE of the number of migrated cells counted in 
10 high-lx~wer fields. 
TSP  (p.g/ml)  UPPER  CHAMBER 
0 
25 
50 
100 
0  25  50  100 
.  23.3"~'~  31.3  37.7  51.3 
Figure 4. Checkerboard analysis of the chemotactic activity of TSP 
on endothelial cells. Different gradient conditions were created by 
adding various concentrations of soluble TSP  to the upper and 
lower compartments of the chamber,  as  indicated.  Motility  re- 
sponse is expressed  as the mean of  triplicate values (standard errors 
were <15%  of the mean). 
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and fucoidan, when added to the lower compartment of the 
Boyden chamber together with TSP,  strongly inhibited the 
chemotactic response of LE-II cells to TSP (Table II). Fucoi- 
dan was a more potent inhibitor of TSP-induced chemotaxis 
of LE-II cells (81%  inhibition at  100/~g/ml) than heparin 
(56 % at the same dose). In both cases the inhibitory effect 
was dose dependent,  and concentrations as low as 1 #g/ml 
(fucoidan) and 10 #g/ml (heparin) significantly reduced the 
motility response. Similarly, the mAb A2.5, directed against 
the amino-terminal heparin binding domain of TSP, strongly 
inhibited (73 % at 50 #g/ml) the chemotactic response of LE- 
II cells to TSP (Table II). This indicates that in endothelial 
cells, as in melanoma cells, the amino-terminal domain of 
TSP is responsible for the induction of chemotaxis. 
Role of lntegrin Receptors in TSP-induced Chemotaxis 
The antibody against the/33 integrin receptor IlbIIIa signifi- 
cantly inhibited the chemotactic response of LE-II cells to 
TSP (Table II), whereas no effect was seen when a  rabbit 
nonimmune serum or an antiserum against laminin were used 
as control (not shown). Therefore, a/33 integrin receptor ap- 
pears to mediate TSP-induced chemotaxis. Antibodies against 
the FN receptor did not inhibit cell migration (Table II) at 
a dose that caused 50 % inhibition of fibronectin-induced LE- 
II chemotaxis (not shown). The same results were obtained 
when chemotaxis was performed using a laminin-coated fil- 
ter, thus showing that the interaction of antibodies with the 
gelatin  substrate was not responsible for the inhibition.  It 
was not possible to establish a role for the GRGDS peptide 
in TSP-induced chemotaxis, since the addition of the peptide 
in the assay prevented endothelial cell attachment to the fil- 
ter, even in the absence of a chemoattractant or using filters 
coated with different substances. 
Modulation of bFGF-induced Chemotaxis by TSP 
Basic FGF is known to induce a chemotactic response in en- 
dothelial  cells  (32).  We  investigated  whether  TSP  could 
modulate the chemotactic response of LE-II cells to bFGE 
Basic FGF (10 ng/ml), in the lower compartment of the Boy- 
den  chamber,  induced  LE-II cell  motility  (2.2  times  the 
background).  The addition  of high concentrations  of TSP 
(100/~g/rnl) to the constant amount of bFGF (10 ng/ml) fur- 
ther  stimulated  LE-II  motility  that  was  higher  (260.3 
migrated cells) than that induced by either TSP (134.7  cells) 
or bFGF (84.7 cells) alone (Fig. 5). When TSP was used at 
nonchemotactic concentrations (0.1 and 0.01 #g/ml) we found 
inhibition of bFGF-induced cell migration (Fig. 5). This was 
not complete (15-61% inhibition) but was reproducible in six 
experiments. 
Inhibition of Growth Response by Soluble TSP 
To test the effect of TSP on LE-II cell growth, two assays 
were used. In the mitogenic assay LE-II cells were grown to 
confluency, TSP with or without growth factors was added 
to quiescent cells,  and incorporation of [3H]thymidine was 
evaluated. In the proliferation assay, cells were counted after 
three days of growth from nonconfluent cultures.  We were 
not able to stimulate [3H]-thymidine incorporation in con- 
fluent and quiescent BAEC (mitogenic assay); BAEC growth 
could only be measured using the proliferation assay. 
Table II. TSP-induced LE-H Chemotaxis: Effect 
of lnhibitors 
Percentage of response* 
Inhibitor  Concentration  (  + SE) 
/z  g  /ml 
Heparin  100  31.7 +  6.1, 
10  45.0  +  8.2* 
1  70.2 +  11.2, 
Fucoidan  100  20.8  +  3.9* 
10  30.5  + 4.5* 
1  65.8 +  14.0, 
A2.5  50  16.8 +  3.2* 
10  88.3 +  11.8 
1  93.1  +  5.9 
Anti IIbl/Ia  1:40  4.3  :t: 3.2, 
Anti FN Rec.  30  116.6 :t: 28.1 
* Results are expressed as a percentage of the migration induced by TSP (50 
#g/ml) without any inhibitor. 
Data represent mean -I- standard error of 2 to 5 different experiments. 
Random motility ranged from  0 to 22 % of maximal response. 
* P  ~  0.001  (t test). 
The presence of TSP alone had no effect on the LE-II mito- 
genesis. However, the addition of soluble TSP to either FCS 
or the angiogenic factor bFGF, resulted in dramatic inhibi- 
tion  of the  mitogenic response of LE-II cells to  the  two 
growth factors. The inhibitory effect of soluble TSP was dose 
dependent, reaching maximal activity at 100 #g/ml (Fig. 6 
a), whereas laminin and fibronectin did not affect the mito- 
genic response at equimolar concentrations. This inhibition 
was always observed in 10 different experiments, and ranged 
T 
0  •  o-  • 
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TSP (p,glml) 
Figure 5. Effect of TSP on bFGF-induced chemotaxis of LE-II cells. 
Different amounts of TSP were added to a constant amount of bFGF 
in the lower compartment of the chamber. Columns represent the 
chemotactic  response induced by 10 ng/ml bFGF alone (left col- 
umn) or in the presence of increasing concentrations of soluble TSE 
The line indicates the motility response induced by each amount of 
TSP alone,  without bFGE Data are expressed as number of mi- 
grated cells in 10 high-power fields. 
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Figure  6.  Effect  of  increasing 
amounts of TSP, LM, and FN on 
FCS-  and  bFOF-induced  mito- 
genesis of LE-II cells.  Different 
concentrations of TSP (ra), LM 
(ta), and FN (0) were added to 
FCS (1%, a) or bFGF (10 ng/ml, 
b). Data are expressed as percent- 
age of the response given by FCS 
or bFGF alone. 
from 25 to 77% reduction of the response obtained with 1% 
serum alone. 
TSP also inhibited the mitogenic effect of bFGF (10 ng/ml) 
on LE-II cells in a dose-dependent manner (Fig. 6 b), the 
reduction ranging from 67 to 84 % in three different experi- 
ments. The inhibitory effect of TSP on serum-induced mito- 
genesis was also observed at higher concentrations of serum 
(Fig. 7).  To preclude the possibility that this inhibition by 
TSP could be the result of cell detachment, parallel experi- 
ments were done as above, except that the cells were washed 
twice with PBS, stained, and counted as for the adhesion as- 
say. The various treatment groups gave similar results, sug- 
gesting that soluble TSP does not induce cell detachment by 
competing for adhesive receptors on the cell surface. The ad- 
dition to the assay of either an antiserum against TSP or 
against the IIblIIa integrin receptor, resulted in cell detach- 
ment from the surface. Thus, it was not possible to measure 
the mitogenic response accurately. 
TSP-inhibition  of  FCS-  or  bFGF-induced  mitogenesis 
resulted in a true inhibition of cell growth, as assessed by the 
proliferation assay, done on both LE-II and BAEC cells. The 
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Figure  7.  Effect of soluble TSP on LE-II mitogenic response to 
FCS. Different amounts of serum were added to quiescent LE-II 
cells, without (ra) or with (•)  soluble TSP (50 #g/ml). After 20 h, 
the mitogenic response was evaluated by [3H]-thymidine  incorpo- 
ration. 
cell count after three days of culture was significantly lower 
(33 and 61% inhibition, respectively) when soluble TSP (50 
#g/ml) was added to the serum (1% for LE-II and 5 % for 
BAEC cells) in the culture medium.  In addition, TSP in- 
hibited the proliferative response of both cell lines to bFGF 
(not shown). 
We found that the GRGDS peptide not only failed to pre- 
vent TSP-mediated inhibition of endothelial cell prolifera- 
tion, but the peptide itself had an inhibitory effect on cell 
growth, probably by interfering with adhesive mechanism of 
the cells. 
The above results indicate an inhibitory effect of soluble 
TSP on endothelial cell growth. In a limited series of experi- 
ments, however, we found that endothelial cell mitogenic and 
proliferative behavior was not significantly affected by sub- 
strate-bound TSP (not shown). 
Discussion 
Endothelial cell attachment, spreading, directed migration, 
and proliferation are basic steps in processes such as angio- 
genesis, wound healing, and tissue remodeling. This study 
reports that TSP can induce adhesion, spreading, and motil- 
ity of murine lung capillary and bovine aortic endothelial 
cells. In addition, TSP inhibits the mitogenic and prolifera- 
tive response of endothelial cells to growth and angiogenic 
factors. 
The adhesive properties of TSP for several cell types have 
been described (9, 14, 20, 34, 35, 42, 43). However, different 
studies  have  produced  conflicting data  on  whether  TSP 
modulates  attachment and  spreading  of endothelial cells. 
Tuszynski et al. described the adhesion of endothelial cells 
on TSP (40).  This was  confirmed by Lawler et al.,  who 
reported that human umbilical vein and arterial endothelial 
ceils adhered on TSP (20). However, these authors found that 
<5 % of the attached cells spread on the TSP substrate (20). 
TSP was also reported to inhibit both adhesion and spreading 
of  BAEC, on either a TSP-coated glass surface, or a fibronec- 
tin surface treated with TSP (17).  The amino-terminal do- 
main of TSP causes loss of focal adhesion plaques on adher- 
ent endothelial cells (27). In our assays, TSP induced both 
adhesion and spreading of LE-II cells and BAEC,  though 
spreading was never as complete as on FN-coated substrate. 
The contrasting data could be related to different soiJrces of 
endothelial cells or differences in methodology. For exam- 
ple, the sensitivity of the TSP receptor(s) to proteases should 
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covery) prevents cell attachment to TSP (40). 
Endothelial cell adhesion on TSP could be influenced by 
de novo synthesis and secretion of other adhesive molecules, 
(i.e., fibronectin). Our data show that for BEAC, but not for 
LE-II cells, endogenous proteins can be responsible for TSP- 
induced cell adhesion. Spreading, however, is only partially 
affected by  inhibitors  of protein  synthesis and  secretion. 
These data suggest that endogenous molecules play a minor 
role in TSP-induced cell adhesion and spreading. 
The migration of endothelial cells induced by ECM com- 
ponents is known to occur in vitro in the process of wound 
healing, and in vivo during angiogenesis. Both LE-II cells 
and  BAEC  migrated  toward  a  gradient  of  soluble  TSP 
(chemotaxis). TSP also induced migration of these cells to 
a  gradient of substrate-bound attractant (haptotaxis), with 
TSP providing both the stimulus and the substrate for cells 
to migrate upon. These data indicate that a gradient of either 
soluble TSP, as in plasma, or substrate-bound TSP, embed- 
ded in the basement membrane or tissues, could induce en- 
dothelial cell migration. The chemotactic properties of TSP 
for human melanoma cells have been described (38). 
TSP contains several possible cell binding domains (9, 19, 
35,  37, 38).  In previous studies we found that the amino- 
terminal heparin binding domain was responsible for TSP- 
induced spreading and chemotactic motility of tumor cells, 
whereas the carboxy-terminal domain mediated tumor cell 
attachment and haptotactic motility, but not spreading (35, 
38).  In this study, we found that heparin and fucoidan in- 
hibited spreading of endothelial cells in response to TSP. 
These data confirm that the heparin binding amino-terminal 
domain of  TSP is responsible for the induction of cell spread- 
ing. In addition, the fact that heparin and fucoidan did not 
completely inhibit attachment indicates the presence of an- 
other cell attachment domain on TSP, as already described 
for tumor cells.  Heparin,  fucoidan,  and the  mAb  A2.5, 
which all bind the amino-terminal small globular region of 
TSP,  inhibited LE-II chemotaxis,  in  agreement with our 
previous findings on tumor cells.  These data confirm that 
different domains of the molecule are responsible for the in- 
duction of specific functions of tumor cells, like those of en- 
dothelial cells. 
This conclusion leads to the hypothesis that at least two 
receptors are involved in the interaction of TSP with cells. 
One receptor would bind to the amino-terminal end of the 
TSP molecule, mediating cell adhesion, spreading, and che- 
motactic response, and could be a heparan sulfate proteogly- 
can or a sulfated glycolipid, as described (14, 27, 33).  An- 
other receptor would bind to the carboxy-terminal end, and 
would mediate cell attachment, but not spreading, and hap- 
totactic motility. This receptor could be the integrin receptor 
related to the IIblIIa, that is reported to bind to the RGDA 
sequence present in the carboxy-terminal region of the mole- 
cule (20, 41). 
However,  the unexpected significant inhibition of adhe- 
sion, spreading, and chemotaxis by the anti-IIblIIa antibody 
indicates that the integrin receptor might be involved in func- 
tions that are not mediated by the RGDA-containing region 
of TSP. A direct interaction between the amino-terminal re- 
gion of TSP and the integrin receptor can be ruled out by the 
findings of Lawler et al. (20), who showed that the interac- 
tion between TSP and its integrin receptor is mediated by the 
RGDA sequence, thus indicating that the receptor binds to 
the carboxy-terminal region. Accordingly, we found that the 
GRGDS peptide affects TSP-mediated endothelial cell ad- 
hesion. 
Another possibility is that the different TSP receptors on 
the cell surface are closely associated, so that binding of the 
Ab to the IIblIIa results in steric hindrance of the interaction 
between the amino-terminal domain of TSP and its receptor. 
However,  we have no direct indication that this association 
of receptors does in fact occur on the cell surface. 
ECM components are known to modulate cell response to 
growth factors. TSP has been described as necessary for the 
proliferation of smooth muscle cells (22, 23). The surprising 
countereffect of TSP on FCS and bFGF might have very im- 
portant  implications.  Endothelial cells  proliferate during 
vessel formation, in embryonic development and in several 
pathologies, including tumor-induced angiogenesis. Several 
agents  have  been  described  as  mitogenic  for endothelial 
cells, and thus possibly important in angiogenesis (7).  TSP 
is reported to be present in the blood vessel wall, in higher 
concentrations at the site of vessel injury. Different authors 
report that TSP is usually associated with undifferentiated 
tissues or cells.  However,  immunocytochemical studies of 
the mouse embryo by O'Shea (29)  indicated that little TSP 
is found irl the early forming vessel, and that it becomes de- 
tectable only at later stages. TSP production by cultured cells 
is  reported  to be  increased by growth  factors,  including 
bFGF (6). On the basis of these data, and on our finding that 
TSP inhibits endothelial cell response to growth factors, one 
could speculate that soluble TSP acts as a regulatory agent 
during the angiogenic process, allowing a feed-back mecha- 
nism. At the site of the lesion, the angiogenic agent (bFGF) 
stimulates the production of TSP (6) which in turn limits the 
angiogenic effect of bFGE 
The mechanism of inhibition of growth response by TSP 
is not known. The possibility that soluble TSP competes with 
growth factors for similar receptors is supported by the fact 
that TSP and several growth factors (like bFGF) can bind to 
heparin and heparan sulfate proteoglycans (3, 8, 9, 28, 32). 
However, there may be some direct interaction of TSP with 
the growth factor molecules. The two possible mechanisms 
are currently under investigation. 
In a preliminary experiment, we found that mAbs directed 
against different domains of the TSP molecule inhibited en- 
dothelial cell growth response to serum and bFGE A similar 
effect has been considered a proof that cell surface TSP is re- 
quired in smooth muscle cells proliferation (23). In our case, 
we  can  hypothesize that endothelial cell  growth requires 
endothelial-derived cell surface TSP, that might be displaced 
by an excess of platelet-derived soluble TSP. Together with 
the finding that substrate-bound TSP had no significant effect 
on endothelial cell growth, this seems to confirm the hypoth- 
esis of Lahav et al., that TSP in different compartments (as- 
sociated to cells or matrix, or soluble) could have different 
physiological functions (18). 
In conclusion, we have shown that TSP stimulates different 
endothelial cell functions potentially related to angiogenesis. 
It also appears to modulate the activity of angiogenic factors. 
Further investigations are necessary to elucidate the physio- 
logical role of TSP in angiogenesis. 
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